Ivonescimab for the Treatment of Thymic Cancer

This study is testing a new drug called ivonescimab for people with thymic carcinoma — a rare cancer of the thymus gland — that cannot be cured with standard treatment. Ivonescimab targets two pathways that help cancer grow: PD-1 (an immune checkpoint) and VEGF (a blood vessel growth factor). **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of incurable thymic carcinoma - You have already tried at least one prior systemic treatment, or are unable to receive other therapies - You are in reasonably good physical health and can carry out daily activities - Your blood counts, kidney, and liver function are within acceptable ranges **You may NOT be eligible if...** - You have already received an immune checkpoint drug targeting PD-1 or PD-L1 - You have uncontrolled high blood pressure, heart problems, or active autoimmune disease requiring immunosuppressant medications - You have certain blood clotting disorders or have had a heart attack or blood clot in the last 6 months - You are pregnant, breastfeeding, or unwilling to use contraception - You have active brain metastases with symptoms Talk to your doctor to see if this trial is right for you.